je.st
news
Home
› ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation For NUPLAZID (Pimavanserin) For Parkinson's Disease Psychosis
ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation For NUPLAZID (Pimavanserin) For Parkinson's Disease Psychosis
2014-09-03 11:32:21| drugdiscoveryonline Home Page
ACADIA Pharmaceuticals Inc. a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders, recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NUPLAZID (pimavanserin) for the treatment of Parkinson’s disease psychosis
Tags: disease
therapy
receives
designation
Category:Biotechnology and Pharmaceuticals